Literature DB >> 17205346

[The management of cutaneous metastases].

C Börgermann1, F Vom Dorp, S Krege, H Rübben.   

Abstract

Cutaneous metastases are rare and usually signify a poor prognosis. The manifestation of cutaneous metastases is variable; crucial to their diagnosis is their inclusion in the differential diagnosis. The therapy occurs mostly with palliative intention. The quality of life of the patient should take first priority. A combination chemotherapy is usually carried out because of systemic progress. For local tumor control and wound care, metastasis surgery and radiotherapy are used.

Entities:  

Mesh:

Year:  2007        PMID: 17205346     DOI: 10.1007/s00120-006-1278-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  6 in total

1.  Cutaneous metastasis from urologic tumors.

Authors:  Prabhash Kumar; N Prasad; G Biswas; P M Parikh
Journal:  Indian J Dermatol Venereol Leprol       Date:  2006 Jan-Feb       Impact factor: 2.545

2.  Cutaneous metastases in renal cell carcinoma.

Authors:  L N Dorairajan; A K Hemal; M Aron; T P Rajeev; M Nair; A Seth; P N Dogra; N P Gupta
Journal:  Urol Int       Date:  1999       Impact factor: 2.089

3.  Cutaneous metastases from transitional cell carcinoma of the bladder.

Authors:  Craig A Block; Laila Dahmoush; Badrinath R Konety
Journal:  Urology       Date:  2006-04-05       Impact factor: 2.649

4.  Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial.

Authors:  T Otto; S Krege; J Suhr; H Rübben
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

Review 5.  Cutaneous metastases from genitourinary malignancies.

Authors:  Thomas J Mueller; Hong Wu; Richard E Greenberg; Gary Hudes; Neil Topham; Stuart R Lessin; Robert G Uzzo
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

6.  Cutaneous metastasis: a meta-analysis of data.

Authors:  Richard A Krathen; Ida F Orengo; Ted Rosen
Journal:  South Med J       Date:  2003-02       Impact factor: 0.954

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.